What's new in WHO fifth edition - urinary tract.
bladder cancer
heterogenous tumours
inverted lesions
molecular stratification
staging
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
01
08
2022
received:
28
04
2022
accepted:
03
08
2022
pubmed:
10
8
2022
medline:
14
9
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
The fifth edition of the WHO Blue Book on urological tumours, specifically in the bladder chapter, represents a refinement and update in the classification of bladder tumours building on the aggregate major changes made in previous editions. Progress in the molecular underpinnings of urothelial tumours, particularly with promising stratifiers for more precision-based treatment approaches, have been made. Special attention has been paid to burning questions in bladder pathology, such as grading, heterogeneous lesions, inverted tumours and substaging. The concept of neuroendocrine tumours will be explained precisely.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-446Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Eble JN, Sauter G, Epstein JI, Sesterhen IA. World Health Organization Classification of Tumour. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Vol. 1. Geneva, Switzerland: World Health Organisation, 2004.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs - part B: prostate and bladder tumours. Eur. Urol. 2016; 70; 106-119.
Berney DM, Cree I, Rao V et al. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology 2022; Online ahead of print. PMID: 35502823. https://doi.org/10.1111/his.14675.
Rindi G, Klimstra DS, Abedi-Ardekani B et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 2018; 31; 1770-1786.
Bertz S, Hartmann A, Knüchel-Clarke R, Gaisa NT. Specific types of bladder cancer. Pathologe 2016; 37; 40-51.
Sylvester RJ, Rodríguez O, Hernández V et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur. Urol. 2021; 79; 480-488.
Soukup V, Čapoun O, Cohen D et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur. Urol. 2017; 72; 801-813.
Mariappan P, Fineron P, O'Donnell M et al. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. World J. Urol. 2021; 39; 425-431.
Compérat E, Amin M, Reuter V. Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading noninvasive bladder cancer: World Health Organisation 1973 or 2004 may be the wrong question. Eur Urol 2019;76;413-415: Two decades of World Health Organisation/International Society of Urological Pathology Bladder Cancer Grading: time to reflect on accomplishments and plan refinement in the molecular era, not regress to readoption of a 45-year-old classification. Eur. Urol. 2019; 76; 416-417.
Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am. J. Surg. Pathol. 1998; 22; 1435-1448.
Compérat E, Larré S, Roupret M et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015; 466; 589-594.
Jones TD, Cheng L. Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP). Histopathology 2020; 77; 525-535.
Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88; 1663-1670.
Gofrit ON, Pizov G, Shapiro A et al. Mixed high and low grade bladder tumors--are they clinically high or low grade? J. Urol. 2014; 191; 1693-1696.
Downes MR, Weening B, van Rhijn BWG, Have CL, Treurniet KM, van der Kwast TH. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. Histopathology 2017; 70; 281-289.
Reis LO, Taheri D, Chaux A et al. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Hum. Pathol. 2016; 47; 20-25.
Eissa A, Zoeir A, Ciarlariello S et al. En-bloc resection of bladder tumors for pathological staging: the value of lateral margins analysis. Minerva Urol. Nefrol. 2020; 72; 763-769.
Murata S, Iseki M, Kinjo M et al. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am. J. Clin. Pathol. 2010; 134; 862-872.
Lopez-Beltran A, Montironi R, Raspollini MR, Cheng L, Netto GJ. Iatrogenic pathology of the urinary bladder. Semin. Diagn. Pathol. 2018; 35; 218-227.
Barkan GA, Wojcik EM, Nayar R et al. The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. J. Am. Soc. Cytopathol. 2016; 5; 177-188.
Wojcik EM, Kurtycz DFI, Rosenthal DL. We'll always have Paris the Paris system for reporting urinary cytology 2022. J. Am. Soc. Cytopathol. 2022; 11; 62-66.
Amin MB, Comperat E, Epstein JI et al. The genitourinary pathology society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia. Adv. Anat. Pathol. 2021; 28; 179-195.
Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am. J. Surg. Pathol. 1996; 20; 1481-1488.
Taguchi S, Watanabe M, Tambo M, Machida H, Yokoyama K, Fukuhara H. Proposal for a new vesical imaging-reporting and data system (VI-RADS)-based algorithm for the management of bladder cancer: a paradigm shift from the current transurethral resection of bladder tumor (TURBT)-dependent practice. Clin. Genitourin. Cancer 2022; 20; e291-e295.
Fransen van de Putte EE, Otto W, Hartmann A et al. Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urol. Oncol. 2018; 36; 361.e7-361.e13.
Leivo MZ, Sahoo D, Hamilton Z et al. Analysis of T1 bladder cancer on biopsy and transurethral resection specimens: comparison and ranking of T1 quantification approaches to predict progression to muscularis propria invasion. Am. J. Surg. Pathol. 2018; 42; e1-e10.
Rouprêt M, Seisen T, Compérat E et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J. Urol. 2013; 189; 2069-2076.
Brierley J, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumours. 8th ed. Oxford, UK/Hoboken, NJ: John Wiley & Sons, Inc., 2017.
Tian W, Epstein JI. Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases. Hum. Pathol. 2015; 46(12); 1836-1841.
Kamoun A, de Reyniès A, Allory Y et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 2020; 77; 420-433.
Robertson AG, Kim J, Al-Ahmadie H et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017; 171; 540-556.e25.
Lopez-Beltran A, López-Rios F, Montironi R, Wildsmith S, Eckstein M. Immune checkpoint inhibitors in urothelial carcinoma: recommendations for practical approaches to PD-L1 and other potential predictive biomarker testing. Cancers 2021; 13; 1424.
Torlakovic E, Lim HJ, Adam J et al. ‘Interchangeability’ of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod. Pathol. 2020; 33; 4-17.
Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018; 554; 544-548.
Powles T, Sridhar SS, Loriot Y et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN bladder 100 trial. Nat. Med. 2021; 27; 2200-2211.
Sangoi AR, Beck AH, Amin MB et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am. J. Surg. Pathol. 2010; 34; 1367-1376.
Raspollini MR, Carini M, Montironi R, Cheng L, Lopez-Beltran A. Mucinous adenocarcinoma of the male urethra: a report of two cases. Anal. Quant. Cytopathol. Histpathol. 2015; 37; 267-272.
Slopnick EA, Bagby C, Mahran A et al. Skene's gland malignancy: a case report and systematic review. Urology 2022; 165; 36-43. https://10.3389/fonc.2022.893980.
Zhang M, Pettaway C, Vikram R, Tamboli P. Adenoid cystic carcinoma of the urethra/Cowper's gland with concurrent high-grade prostatic adenocarcinoma: a detailed clinicopathologic case report and review of the literature. Hum. Pathol. 2016; 58; 138-144.